Press Releases OncoZenge AB

Equities

ONCOZ

SE0015504097

Market Closed - Nasdaq Stockholm Other stock markets 16:29:40 10/05/2024 BST			5-day change	1st Jan Change
3.955 ^SEK	+2.20%		+2.99%	+27.99%

04-08	Oncozenge AB Appoints Paolo Bossi as Member of the Advisory Board	CI
04-04	OncoZenge Announces Read-Out of Positive Stability Data for BupiZenge	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

OncoZenge Appoints Anna Asplind as Phase 3 Program Manager	04-26	AQ
OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs	04-25	AQ
OncoZenge Appoints Åsa Nilsson as Clinical Research Manager	04-09	AQ
OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board	04-08	AQ
OncoZenge Announces Read-out of Positive Stability Data for BupiZenge™	04-04	AQ
OncoZenge Explores Strategic Options for BupiZenge™ in China	03-11	AQ
OncoZenge Files Patent Application for Strengthened IP Protection for BupiZenge™	02-07	AQ
OncoZenge submits application for PRIME status in the EU	01-02	AQ
OncoZenge Announces Advisory Board with Dr Stephen Sonis and Dr Pooja Nandwani Patel	12-13	AQ
Ensysce Biosciences Discusses TAAP and MPAR Applications and OncoZenge Partnership with the Stock Day Podcast	12-12	AQ
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge™ in the United States	11-28	AQ
OncoZenge provides strategy update	11-24	AQ
The new formulation of OncoZenge's drug candidate BupiZenge™ is clean	11-21	AQ
OncoZenge initiates toxicity study and announces modification to the clinical plan	15/02/22	AQ
Moberg Pharma AB : Interim report January - March 2021	11/05/21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer